J Korean Ophthalmol Soc.  2011 Jul;52(7):788-793. 10.3341/jkos.2011.52.7.788.

Therapeutic Effects of Periocular Injection of Triamcinolon Acetonide in Patients with Thyroid-Associated Ophthalmopathy

• Kim JE
• Park JW
• Cho JK
• Yoon KC

• KMID: 2214702
• DOI: http://doi.org/10.3341/jkos.2011.52.7.788

Abstract

PURPOSE
The present study investigated the therapeutic effects of periocular triamcinolone acetonide injections to treat inflammatory signs in patients with severe acute thyroid-associated ophthalmopathy.
METHODS
Twenty-two patients with symptoms of severe acute thyroid ophthalmopathy were enrolled in the present study. The patients received four doses of 20 mg of triamcinolone acetonide via periocular injection into the inferotemporal orbital quadrant every 2 weeks. The changes in visual acuity, intraocular pressure, eye ball motility, exophthalmos, thickness of extraocular muscles, clinical activity score and NOSPECS score were measured.
RESULTS
Eighteen of 22 patients (81.8%) showed improvement in soft tissue swelling, ten patients (45.5%) showed improvement in conjunctival hyperemia and one patient showed improvement of ocular motility. Clinical activity score and NOSPECS score had significant improvements. No patient had changes in visual acuity, intraocular pressure, diplopia, proptosis or thickness of extraocular muscles. An ocular adverse effect was found in one patient, who had subcutaneous fat atrophy at the injection site.
CONCLUSIONS
In patients with severe acute thyroid ophthalmopathy, periocular triamcinolone acetonide injection can be effective to improve acute inflammatory symptoms, without significant adverse effects.

Keyword

Periocular injection; Thyroid-associated ophthalmopathy; Triamcinolone

MeSH Terms

Atrophy
Diplopia
Exophthalmos
Eye
Graves Ophthalmopathy
Humans
Hyperemia
Injections, Intraocular
Intraocular Pressure
Muscles
Orbit
Subcutaneous Fat
Thyroid Gland
Triamcinolone
Triamcinolone Acetonide
Visual Acuity
Triamcinolone
Triamcinolone Acetonide

Reference

References

1. Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006; 142:147–53.

2. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am. 1987; 16:391–407.

3. Bordaberry M, Marques DL, Pereira-Lima JC, et al. Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves' ophthalmopathy. Acta Ophthalmol. 2009; 87:58–64.

4. Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004; 88:1380–6.

5. Poonyathalang A, Preechawat P, Charoenkul W, Tangtrakul P. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai. 2005; 88:345–9.

6. Jung BY, Kim YD. The results of periocular injections of triamcinolone for thyroid orbitopathy. J Korean Ophthalmol Soc. 2007; 48:1163–9.

7. Sergott RC, Glaser JS. Graves' ophthalmopathy. A clinical and immunologic review. Surv Ophthalmol. 1981; 26:1–21.

8. Garber MI. Methylprednisolone in the treatment of exophthalmos. Lancet Lancet. 1966; 1:958–60.

9. Werner SC. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977; 44:203–4.

10. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol. 1997; 47:9–14.

11. Park JM, Ahn HB, Lee JH. The clinical features and the change of extraocular muscle at the first visit in hyperthyroidism patients. J Korean Ophthalmol Soc. 2003; 44:2197–203.

12. Hallin ES, Feldon SE. Graves' ophthalmopathy: I. Simple CT estimates of extraocular muscle volume. Br J Ophthalmol. 1988; 72:674–7.

13. Chen YL, Chang TC, Huang KM, et al. Relationship of eye movement to computed tomographic findings in patients with Graves' ophthalmopathy. Acta Ophthalmol (Copenh). 1994; 72:472–7.

14. Bartalena L, Marcocci C, Pinchera A. Treating severe Graves' ophthalmopathy. Baillieres Clin Endocrinol Metab. 1997; 11:521–36.

15. Koornneef L. New insights in the human orbital connective tissue. Result of a new anatomical approach. Arch Ophthalmol. 1977; 95:1269–73.

16. Koornneef L. Orbital septa: anatomy and function. Ophthalmology. 1979; 86:876–80.

17. O'Connor GR. Periocular corticosteroid injections: uses and abuses. Eye Ear Nose Throat Mon. 1976; 55:83–8.

18. Jordan DR, Brownstein S, Lee-Wing MW, Coupal D. Orbital mass following injection with depot corticosteroids. Can J Ophthalmol. 2001; 36:153–5.

19. Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection. Am J Ophthalmol. 1976; 82:928–30.

20. Droste PJ, Ellis FD, Sondhi N, Helveston EM. Linear subcutaneous fat atrophy after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol. 1988; 105:65–9.